

Foreword

Teiichi Goto

Director, Senior Vice President
FUJIFILM Corporation



The healthcare business of Fujifilm is striving to further enhance the quality of life of people worldwide by leveraging the group's extensive range of products, service and technology accumulated to date as a comprehensive healthcare company encompassing wide-ranging business relating to people's health, from diagnosis, treatment and prevention.

The starting point of the business of the "diagnosis" field goes back to the launch of "X-ray film" in 1936 soon after the company foundation. Ever since, the company continues to expand the domain of "diagnosis" with medical equipment including digital X-ray diagnostic imaging system "FCR", "FUJIFILM DR", endoscope system, in-vitro diagnostic system and ultrasound diagnostic equipment as well as "SYNAPSE" the medical-use picture archiving and communications systems (PACS) and radioactive diagnostic agent.

To make a leap forward in the "treatment" field, we acquired Toyama Chemical Co., Ltd., a drug developing company with strength in infectious disease and anti-inflammation in 2008 and made a full-scale entry into the treatment field.

In the "diagnosis" field, Fujifilm released FCR5000M, a digital X-ray diagnostic imaging system (mammography devices) for breast cancer screening in 2000. Breast cancer is the number one cancer of women but is a disease that can be cured with high probability with early detection. Various types of diagnostic equipment have been developed for breast cancer examination, but it is only the mammography system that has proved to reduce the death rate through screening. Our company is continuing to add new proprietary technology to the breast X-ray diagnosis system to realize high-resolution and minimally invasive screening. We have been putting special effort in the development of mammography in the overall medical systems business as we aspire to contribute to the society with early detection of breast cancer.

Fujifilm released its first DR type digital mammography system "AMULET" in October 2008, "AMULET f/s" in 2011 and "AMULET Innovality" in 2013. To commemorate the AMULET series achieving accumulated sales of over 4000 units, the 63rd issue of FUJIFILM RESEARCH & DEVELOPMENT will be featuring "AMULET Innovality."

The mammography system of our company combines material synthesis technology, image generation technology and image processing technology at the most advanced level. The tomosynthesis function which significantly improved the acquiring ability of images of tumors or other lesion is a function achieved from our proprietary image technology. This issue covers the clinical effect and associated technology of the tomosynthesis function.

Ever since our company first digitalized the X-ray image in the world, we have been pursuing technology that can only be made possible by digitalization. We will continue to address the changes in the market with agility and utilize AI and ICT technology for our product portfolio in the mammography field to continuously develop and create new value to protect the daily happiness and wellbeing of all women and their beloved ones.